BMS Buys Into Hengrui 13-Asset Pipeline for $950M
BMS commits $950M up front for a 13-asset onco-immune pipeline with Hengrui that could balloon to $15.2B if every milestone clears.
BMS commits $950M up front for a 13-asset onco-immune pipeline with Hengrui that could balloon to $15.2B if every milestone clears.
Judge Hoyt granted acquittal after DOJ left translators off the witness stand. Now the government takes its Sixth Amendment loss to the Fifth Circuit.
Payward already holds a Fed master account; an OCC trust charter would complete the picture, but BPI may sue to shut the whole pipeline down.
GitLab is flattening up to three layers of management, splitting R&D into 60 autonomous teams, and routing internal reviews, approvals, and handoffs through AI agents.
CSL's $5B write-down paired with a 4% guidance cut drove shares to a nine-year low; investors aren't convinced the cleanup is done.
A federal bill filed April 20 would ban AI chatbot toys outright. If your API powers one, the vetting gap you ignored is about to become your problem.
A German suspect rebuilt Crimenetwork within days of its 2024 shutdown, attracted 22,000 users and €3.6M, then got arrested in Mallorca.
Peter Williams, who ran L3Harris's hacking-tools unit, got a $10M restitution order Wednesday. Russian spies later used the stolen tools in Ukraine.
WSJ reports Trump plans to fire FDA Commissioner Makary after 14 months marked by mass departures, a vaping feud, and warnings of political capture.
WSJ reports Trump plans to oust FDA Commissioner Makary after 14 months of unprecedented turnover and a White House battle over flavored vapes.
France has escalated its X content probe to a criminal case against Musk and Yaccarino, who could face indictment if they don't appear.
The CBLR's revised eligibility rules and recalibrated leverage ratio mean every community bank must decide by July 1 if it still qualifies.
Trump's 100% drug tariff has a two-tier problem: big pharma cut deals, small- and mid-sized drugmakers are still in the line of fire.
FDA classified Biogen and Eisai's Leqembi SubQ initiation filing as a major amendment, moving the verdict from May 24 to August 24.
Odyssey Therapeutics priced a $304M IPO at $18 per share, at the top of its range, with $135M earmarked for a RIPK2 inhibitor in ulcerative colitis.